trending Market Intelligence /marketintelligence/en/news-insights/trending/uxrpn2bfmtlhh0khbs355a2 content esgSubNav
In This List

Vascular Biogenics director resigns

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Vascular Biogenics director resigns

Philip Serlin resigned as director of Vascular Biogenics Ltd.

Serlin's resignation did not result from any disagreement with Vascular Biogenics on any matter relating to its operations, policies or practices, according to the company.

Israel-based Vascular Biogenics is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of treatments for cancer.